Article
The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting - 1 Jan 2013
Keohane Clodagh, Mesa Ruben, Harrison Claire
Abstract excerpt
In 2005, the description of the JAK2V617F mutation for the first time provided a molecular key to enable more rapid diagnosis and target for novel therapeutics in the myeloproliferative neoplasms. In 2007, the first-in-class agent INC18424, ruxolitinib, JAKafi, or JAKAVI was first tested in patients with intermediate-risk 2 or high-risk myelofibrosis regardless of whether they possessed the JAK2V617F mutation....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.